Analyzing tumor tissue samples from patients with advanced ovarian cancer

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This research focuses on analyzing tumor tissue samples from patients who have undergone surgery for advanced stage III or IV ovarian epithelial cancer. The primary objective is to validate the ability of tumor-infiltrating lymphocytes (TILs) to predict progression-free survival and overall survival in patients based on the status of their debulked disease. The study utilizes previously collected tumor samples and employs laboratory techniques such as immunohistochemistry and double immunofluorescence assays to assess the presence of TILs. By understanding the role of TILs, the study aims to provide insights into patient responses to treatment.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Diagnosis of stage III or IV ovarian epithelial cancer and enrolled on Gynecologic Oncology Group (GOG)-0136 and a GOG front-line platinum/taxol chemotherapy trial (GOG-0114, GOG-132, GOG-0158, or GOG-0162)
* Must have fixed and paraffin-embedded tissue from primary surgery available from 1 of the following sources:

  * Patients enrolled on GOG-0136 and a GOG front-line platinum/taxol chemotherapy trial(GOG-0114, GOG-0132, GOG-0158, and GOG-0162)
  * Patients who have had either optimal or suboptimal cytoreductive surgery
  * Patients for whom adequate demographic data, including major prognostic factors and follow-up information, were collected
* Evaluable patients must have had measurable or nonmeasurable disease
* Demographic and follow-up data available

Where it's running

• Gynecologic Oncology Group
  Philadelphia, Pennsylvania, United States Recruiting

Study contacts

• Principal investigator: George Coukos — Gynecologic Oncology Group

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Testing a new dosing method of niraparib for ovarian cancer treatment

  This study is testing a new way to give niraparib to see if it helps people with newly diagnosed advanced ovarian cancer stay healthy longer after their initial chemotherapy.

  Recruiting Phase 2 Sunnybrook Health Sciences Centre · Toronto, Ontario · NCT05961124

• Heated chemotherapy followed by Niraparib for advanced ovarian cancer

  This study is testing if a heated chemotherapy treatment followed by a drug called Niraparib can help people with advanced ovarian cancer do better after surgery compared to regular chemotherapy.

  Recruiting at 59 sites Phase 3 GOG Foundation · Duarte, California and 58 other locations · NCT05659381

• Comparing stress reduction methods to standard care for ovarian cancer patients

  This study is testing if a mix of medications and therapies can help reduce stress in women with advanced ovarian cancer before their surgery, compared to those getting standard care.

  Recruiting at 7 sites Memorial Sloan Kettering Cancer Center · Basking Ridge, New Jersey and 6 other locations · NCT05429970

• CAR-NK cell therapy for advanced solid tumors

  This study is testing a new treatment using specially modified immune cells to see if they can help people with advanced solid tumors like ovarian and testis cancers.

  Recruiting Phase 1 Second Affiliated Hospital of Guangzhou Medical University · Guangzhou, Guangdong · NCT05410717

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.